Esoferr Drug Interactions

The absorption of ketoconazole and itraconazole can decrease during treatment with esomeprazole.
When esomeprazole is combined with drugs metabolized by CYP2C19, such as diazepam, citalopram, imipramine, clomipramine, phenytoin etc., the plasma concentrations of these drugs may be increased and a dose reduction could be needed. It is recommended to monitor the plasma concentrations of phenytoin when treatment with esomeprazole is introduced or withdrawn. Monitoring is recommended when initiating and ending concomitant esomeprazole treatment with warfarin or other coumarin derivatives.
Esomeprazole has been shown to have no clinically relevant effects on the pharmacokinetics of amoxicillin or quinidine.
DR cap: The gastric acid suppression during treatment with esomeprazole and other PPIs might decrease or increase the absorption of drugs with gastric pH dependent absorption.
The absorption of erlotinib can decrease during treatment with esomeprazole.
The absorption of digoxin can increase during treatment with esomeprazole.
Concomitant administration of 40 mg esomeprazole and cisapride, resulted increase in area under the plasma concentration-time curve (AUC) and prolongation of elimination half-life (t_1/2) but no significant increase in peak plasma levels of cisapride.
Omeprazole has been reported to interact with some antiretroviral drugs. Increased gastric pH during omeprazole treatment may change the absorption of the antiretroviral drug. For some antiretroviral drug, such as atazanavir and nelfinavir, decreased serum level has been reported when given together with omeprazole. Due to similar pharmacodynamic effects and pharmacokinetic properties of omeprazole and esomeprazole, esomeprazole should not be coadministered with atazanavir and nelfinavir.
Concomitant administration of esomeprazole and either naproxen or rofecoxib did not identify any clinically relevant pharmacokinetic interactions.
Concomitant administration of esomeprazole and a CYP3A4 inhibitor, clarithromycin (500 mg b.i.d), resulted in a doubling of the exposure (AUC) to esomeprazole.
Drug known induce CYP2C19 or CYP3A4, or both (such rifampicin and St. John's wort) may lead to decrease esomeprazole serum level and increasing the esomeprazole metabolism.
Powd for inj: Concomitant administration with esomeprazole and atazanavir is not recommended.
Concomitant administration of esomeprazole and a combined inhibitor of CYP2C19 and CYP3A4, such as voriconazole, may result in more than doubling of the esomeprazole exposure.